Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE1B | Q01064 | 3/20 | 0.37 |
| ▸ | PDE1A | P54750 | 1/20 | 0.36 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | GRM2 | Q14416 | 3/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | PDE2A | O00408 | 1/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.34 |
| ▸ | PDE4A | P27815 | 1/20 | 0.34 |
| ▸ | ABCC8 | Q09428 | 1/20 | 0.33 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL674937 | 0.94 | PDE1B (0.37) | PDE1BPDE1APDE1CKMT2AMEN1 | |
| SCHEMBL678944 | 0.88 | PDE1B (0.36) | PDE1BPDE1APDE1CKMT2AMEN1 | |
| SCHEMBL674429 | 0.87 | ALDH1A1 (0.43) | GRM2LMNAADORA3 | |
| SCHEMBL676398 | 0.86 | PTGS2 (0.46) | PDE1BPDE1APDE1CKMT2AMEN1 | |
| SCHEMBL680017 | 0.85 | PDE1B (0.41) | PDE1BPDE1APDE1CKMT2AMEN1 | |
| SCHEMBL676359 | 0.84 | PDE1B (0.42) | PDE1BPDE1APDE1CKMT2AMEN1 | |
| SCHEMBL676325 | 0.83 | DPP4 (0.37) | PDE1BPDE1APDE1CKMT2AMEN1 | |
| SCHEMBL676897 | 0.82 | MAOB (0.38) | PDE1BPDE1APDE1CGRM2LMNA | |
| SCHEMBL678934 | 0.81 | PDE1B (0.40) | PDE1BPDE1APDE1CKMT2AMEN1 | |
| SCHEMBL676517 | 0.81 | PDE1B (0.54) | PDE1BPDE1APDE1CKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8859564-B2 | Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione derivatives useful as inhibitors of phosphodiesterase 1 | INTRA-CELLULAR THERAPIES, INC. (US) | 2014-10-14 | — | — | US | disclosed |
| US-20110281832-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. | 2011-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110281832-A1 | ORGANIC COMPOUNDS | CYP2C9, CYP2C19, CYP3A4 | PDE1B 4855/4885PDE1A 4874/4885PDE1C 4854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.